A Modeling Framework to Characterize Cytokine Release upon T‐Cell–Engaging Bispecific Antibody Treatment: Methodology and Opportunities
T‐cell–engaging bispecific antibodies (T‐BsAbs) are an important class of antibody therapeutics in immuno‐oncology. T‐BsAbs simultaneously bind to CD3 on T cells and a tumor‐associated antigen on tumor cells, activate T cells, and redirect T cells’ cytotoxicity against tumor cells. Cytokine release...
Main Authors: | Xiaoying Chen, Cris Kamperschroer, Gilbert Wong, Dawei Xuan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-11-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.12662 |
Similar Items
-
Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
by: Ames C. Register, et al.
Published: (2021-05-01) -
VHH-Based Bispecific Antibodies Targeting Cytokine Production
by: Maxim A. Nosenko, et al.
Published: (2017-09-01) -
Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
by: Lawrence G Lum, et al.
Published: (2021-05-01) -
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
by: Lauric Haber, et al.
Published: (2021-07-01) -
Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics
by: Cris Kamperschroer, et al.
Published: (2020-01-01)